The invention relates to a method of determining the prognosis and suitable treatment of cancer in a subject by measuring the level of expression of SPAG5. In particular, it relates to a method where high expression of SPAG5 in tumour cells correlates with aggressive tumours especially breast and ovarian cancers.
SPAG5 has been found to be involved in the functional and dynamic regulation of mitotic spindles, and to be essential for progression through mitosis and chromosome segregation fidelity. It is an aim of the present invention to provide a biomarker that may be used to give an indication of the prognosis of cancer in an individual and/or which may also be used to assess the type of treatment that is appropriate for a particular tumour or individual.
High expressions of SPAG5 may indicate that the tumour is likely to be sensitive to a platinum chemotherapy agent or an anthracycline, whereas a low expression of SPAG5 may indicate that the tumour is likely to be resistant to the therapy.
Benefits and applications
- Ability to stratify breast cancer and ovarian cancer patients more accurately for platinum chemotherapy or anthracycline treatment in order to gain maximal clinical benefit and increase the success rate of the therapy.
Professor Graham Ball
The John Van Geest Cancer Research Centre